Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023 - Seite 2

Mr. Fair continued, "The marked growth in revenue for 2023 is a result of a well-executed plan of geographic and sales channel expansion led by our expert sales, marketing, and customer service teams. In addition, our continued investment in innovation, and operational excellence in manufacturing, quality, and logistics has ensured that we can meet and exceed our customers' demands, ensuring that no patient will miss treatment. With our recent decision to focus our financial resources on the MagnetOs technology and associated portfolio of products, and not to proceed into Phase 3 with Fibrin-PTH, we have made significant progress toward reaching a cash flow break-even point more quickly. These strong financial results underline our commitment to increasing shareholder value by balancing high sales growth with targeted profitability."

Key developments in 2023 and so far in 2024

February 16, 2023	Kuros Biosciences announces changes to Executive Management Team
February 21, 2023	Kuros Biosciences announces publication of supportive osteoimmunology data for MagnetOs bone graft
March 15, 2023	Kuros Biosciences reports results for the full year 2022
April 27, 2023	Kuros Biosciences reports 168% increase in direct MagnetOs sales in the first quarter of 2023
May 8, 2023	Annual General Meeting of Kuros Biosciences approves all resolutions
July 13, 2023	Kuros Biosciences announces completion of enrollment in the Fibrin-PTH Phase 2 trial
August 9, 2023	Kuros Biosciences reports results for first half 2023
October 12, 2023	Kuros Biosciences reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within Executive Management Team
November 28, 2023	Kuros Biosciences receives US FDA 510(k) clearance for use of MagnetOs in interbody spinal cages
December 20, 2023	Kuros Biosciences receives US FDA 510(k) clearance for use of MagnetOs Putty standalone
December 27, 2023	Kuros Biosciences announces results from two prospective randomized clinical trials: STRUCTURE and MAXA
January 4, 2024	Kuros Biosciences announces three advancements related to its MagnetOs portfolio including impressive fusion data from MAXA prospective randomized clinical trial and two 510(k) clearances from FDA
January 31, 2024	Kuros Biosciences receives US FDA 510(k) clearance for MagnetOs Granules for interbody use and regulatory clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
February 1, 2024	Kuros Biosciences presents at the CG 2024 Musculoskeletal Conference

Group financial results